---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-010408"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T11:09:18.233933+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Abeona reports $71.2M net income in FY 2025; first ZEVASKYN patient treated

## Summary
- First ZEVASKYN commercial patient treated in Dec 2025; net product revenue $2.4M; one patient treated in Q1 2026 with more biopsies collected.
- Total revenue $5.8M including $3.4M license revenue from Taysha milestone; PRV sale net gain $152.4M.
- Net income $71.2M ($1.34 basic EPS) vs loss of $63.7M in 2024; cash $191.4M as of Dec 31, 2025.
- R&D spend decreased to $26.8M; SG&A increased to $65.0M due to commercial transition post-FDA approval.
- Expanding patient access: fourth QTC activated at UTMB Galveston; building launch momentum.

## SEC filing metadata
- accession: 0001493152-26-010408
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/0001493152-26-010408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-010408
- JSON: https://secwatch.observer/filing/0001493152-26-010408.json
- Plain text: https://secwatch.observer/filing/0001493152-26-010408.txt

## Key facts
- Earnings Releases
  ABEONA THERAPEUTICS INC. reported year ended December 31, 2025 results: revenue $5.8 million, net income $71.2 million, EPS $1.34 per basic and $1.01 per diluted common share.
  - Period: year ended December 31, 2025
  - Revenue: $5.8 million
  - Net income: $71.2 million
  - EPS: $1.34 per basic and $1.01 per diluted common share
  - Result: reported results
  source text: Abeona reported total revenue of $5.8 million for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/0001493152-26-010408-index.htm
- Earnings Releases
  ABEONA THERAPEUTICS INC. reported year ended December 31, 2025 results: revenue $5.8 million, net income $71.2 million, EPS $1.34 per basic and $1.01 per diluted common share.
  - Period: year ended December 31, 2025
  - Revenue: $5.8 million
  - Net income: $71.2 million
  - EPS: $1.34 per basic and $1.01 per diluted common share
  - Result: reported results
  source text: major academic medical center renowned for its expertise in comprehensive complex skin disease and wound care. Full Year 2025 Financial Results Abeona reported total revenue of $5.8 million for the year ended December 31, 2025. This was comprised of $3.4 million in license and other revenues and $2.4 million in net product revenue. License and other revenues were
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/0001493152-26-010408-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.